Chlamydia Infection Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other), By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection), By End User (Hospitals, Specialty Clinics, Diagnostics Centre), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 771.12 Million
CAGR (2026-2031)	6.67%
Fastest Growing Segment	Hospitals
Largest Market	North America
Market Size (2031)	USD 1135.99 Million

Market Overview

The Global Chlamydia Infection Diagnostics Market will grow from USD 771.12 Million in 2025 to USD 1135.99 Million by 2031 at a 6.67% CAGR. Chlamydia infection diagnostics consist of laboratory assays and rapid testing kits, primarily utilizing Nucleic Acid Amplification Tests, designed to identify the Chlamydia trachomatis bacterium in patient samples. The market is fundamentally supported by the persistent global prevalence of sexually transmitted infections and the robust implementation of government-mandated screening programs aimed at early disease detection. According to the Centers for Disease Control and Prevention, in 2025, provisional surveillance data indicated that approximately 1.5 million cases of chlamydia were reported in the United States during 2024, underscoring the sustained demand for reliable testing solutions despite fluctuations in annual infection rates.

A significant challenge impeding market expansion is the frequently asymptomatic nature of chlamydia infections, which leads to a lack of urgency among patients to seek medical advice. Because a vast number of infected individuals exhibit no clinical signs, they often remain undiagnosed and untreated, thereby restricting the overall volume of diagnostic procedures performed annually. This characteristic creates a dependency on proactive public health initiatives rather than symptomatic patient visits, limiting market penetration in regions where routine screening is not strictly enforced.

Key Market Drivers

The Increasing Global Incidence of Chlamydia Trachomatis Infections acts as a primary market catalyst, necessitating robust surveillance to mitigate the spread of this pervasive bacterial infection. As transmission rates persist, healthcare systems are prioritizing widespread screening to identify untreated populations and prevent complications such as infertility. This elevated burden drives a sustained requirement for high-volume laboratory testing. According to MedTech Dive, March 2025, in the article 'FDA OKs first at-home test for 3 STIs', data from the Centers for Disease Control and Prevention indicated that more than 2.4 million cases of syphilis, gonorrhea, and chlamydia were collectively reported in the U.S. during 2023. Such statistics reinforce the need for continuous monitoring. According to the UK Health Security Agency, December 2025, in the 'Sexually transmitted infections and screening for chlamydia in England: 2024 report', 601,295 chlamydia tests were carried out among young women aged 15 to 24 years in England during 2024, illustrating the massive operational scale of national screening efforts.

The Proliferation of Rapid Point-of-Care (POC) Diagnostic Technologies and Rising Consumer Demand for At-Home Testing Kits are reshaping market dynamics by decentralizing access to care. These innovations address patient barriers related to privacy and convenience, encouraging individuals who might otherwise avoid clinical settings to seek diagnosis. Regulatory bodies are increasingly validating these platforms, allowing for broader commercialization. According to CIDRAP, March 2025, in the article 'FDA approves at-home test for sexually transmitted infections', the U.S. FDA granted marketing authorization for the first at-home, over-the-counter test from Visby Medical capable of detecting chlamydia, gonorrhea, and trichomoniasis. This shift toward user-initiated diagnostics potentially increases detection rates by capturing asymptomatic cases that traditional clinical pathways often miss.

Download Free Sample Report

Key Market Challenges

The significant challenge impeding the expansion of the Global Chlamydia Infection Diagnostics Market is the frequently asymptomatic nature of the infection, which creates a substantial barrier to voluntary testing. Because the majority of infected individuals do not experience noticeable symptoms, they lack the immediate motivation to seek medical attention or undergo diagnostic screening. This disconnect significantly reduces the volume of patient-initiated visits, making the market heavily dependent on government-funded screening initiatives rather than consumer demand. When public health resources are strained or screening programs are not rigorously enforced, the number of tests performed declines sharply, directly limiting the revenue potential for diagnostic manufacturers.

This trend is evident in recent surveillance data which highlights how reduced testing activity correlates with lower detection rates. According to the UK Health Security Agency, in 2025, national statistics revealed that chlamydia diagnoses decreased by 13 percent in 2024 compared to the previous year, a decline primarily attributed to a reduction in testing volumes among young adults. This contraction in diagnostic activity underscores how the absence of clinical symptoms allows infections to go undetected, thereby reducing the addressable market size for diagnostic testing solutions.

Key Market Trends

The Widespread Implementation of Multiplex Nucleic Acid Amplification Assays is transforming diagnostic workflows by enabling the simultaneous detection of Chlamydia trachomatis alongside common co-infections such as Neisseria gonorrhoeae and Trichomonas vaginalis. This shift addresses the clinical necessity for comprehensive sexual health profiling, as identifying multiple pathogens in a single run significantly improves patient management and laboratory efficiency compared to utilizing separate, single-target tests. According to Hologic, Inc., November 2025, in the 'Financial Results for Fourth Quarter of Fiscal 2025', the company’s molecular diagnostics revenue increased by 1.2 percent, a growth trajectory explicitly driven by the rising adoption of their advanced multiplex panels, including the BV CV/TV assays, which consolidate testing for vaginitis and sexually transmitted pathogens on their automated platforms.

Simultaneously, the Emergence of Decentralized Pharmacy-Based Screening Models is redefining patient access by integrating diagnostic services into community retail settings, thereby removing barriers associated with traditional clinical visits. By leveraging the accessibility of local pharmacies, public health programs are increasingly utilizing these locations to distribute self-collection kits and facilitate immediate intervention, effectively reaching asymptomatic populations who might otherwise forego routine medical appointments. According to Surrey County Council, February 2025, in the 'Chlamydia Treatment and Screening 2025-28' agreement, the authority formalized a service specification requiring community pharmacies to actively supply chlamydia screening kits to sexually active individuals under 25, underscoring the strategic shift toward pharmacy-led infrastructure in managing infection rates.

Segmental Insights

The Hospitals segment is recognized as the fastest-growing category in the Global Chlamydia Infection Diagnostics Market due to the rising volume of patient visits for sexually transmitted disease screenings. This expansion is supported by the comprehensive infrastructure within hospitals that allows for accurate testing and immediate clinical intervention. Additionally, guidelines from the Centers for Disease Control and Prevention encouraging routine testing in healthcare facilities further drive patient traffic to these institutions. The capability of hospitals to provide integrated diagnosis and treatment services significantly increases the utilization of diagnostic tests in this sector.

Regional Insights

North America dominates the global chlamydia infection diagnostics market primarily due to the high prevalence of sexually transmitted infections and substantial healthcare expenditure. The region benefits from established screening guidelines endorsed by the Centers for Disease Control and Prevention, which encourage regular testing among high-risk populations. Additionally, the presence of key industry players and frequent product approvals by the U.S. Food and Drug Administration facilitate the availability of accurate diagnostic tools. Favorable reimbursement policies further support the widespread adoption of these tests across clinical settings.

Recent Developments

• In March 2025, Visby Medical received marketing authorization from the U.S. Food and Drug Administration for the first over-the-counter, at-home diagnostic test for sexually transmitted infections. This single-use, instrument-free polymerase chain reaction (PCR) device was cleared to detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis using self-collected vaginal swabs. The authorization marked a significant milestone in the diagnostics market, as it allowed consumers to obtain molecular-grade results in under 30 minutes without a prescription or the need to mail samples to a laboratory. This breakthrough aimed to empower individuals with immediate health information and facilitate faster linkage to treatment.
• In February 2025, Abbott secured 510(k) clearance from the U.S. Food and Drug Administration for its Simpli-COLLECT STI Test, a novel self-collection kit for sexual health screening. This product was authorized for the home collection of urogenital specimens, which could then be processed in a clinical laboratory to detect nucleic acids from Chlamydia trachomatis and Neisseria gonorrhoeae. The clearance addressed the growing demand for private and convenient testing options, removing barriers associated with traditional clinic-based sample collection. By enabling patients to gather their own samples in a comfortable environment, the company aimed to improve screening compliance and early detection rates.
• In January 2025, Roche announced that it had received 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration for its new point-of-care multiplex assay panels. These diagnostics were designed to run on the cobas liat system and allowed healthcare providers to detect and differentiate Chlamydia trachomatis and Neisseria gonorrhoeae within 20 minutes using a single sample. The approval enabled the use of these molecular tests in non-traditional laboratory settings, such as urgent care clinics. This launch expanded access to rapid, accurate confirmatory testing, facilitating immediate treatment decisions during a single patient visit.
• In June 2024, Fuse Diagnostics was awarded funding of up to US$1 million by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance the development of an innovative diagnostic solution. This collaboration focused on demonstrating the proof-of-concept for a rapid, instrument-free test designed to detect Chlamydia trachomatis and Neisseria gonorrhoeae. The company utilized this investment to validate the performance of its Apex test on clinical samples, aiming to provide a low-cost, decentralized testing option. This initiative addressed the critical need for accessible diagnostics to combat the spread of sexually transmitted infections and antibiotic resistance in resource-limited settings.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Hologic, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc
• Quidel Corporation
• DiaSorin SpA
• AstraZeneca Plc
• Teva Pharmaceutical Industries Limited
• bioMérieux SA

By Test Type	By Type of Infections	By End User	By Region
Culture Test Nucleic Acid Amplification Test (NAAT) Direct Fluorescent Antibody Test Serology Test and Other	Genital Chlamydia Infection Rectal Chlamydia Infection Ocular Chlamydia Infection	Hospitals Specialty Clinics Diagnostics Centre	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Chlamydia Infection Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Chlamydia Infection Diagnostics Market, By Test Type:

• Culture Test
• Nucleic Acid Amplification Test (NAAT)
• Direct Fluorescent Antibody Test
• Serology Test and Other

• Chlamydia Infection Diagnostics Market, By Type of Infections:

• Genital Chlamydia Infection
• Rectal Chlamydia Infection
• Ocular Chlamydia Infection

• Chlamydia Infection Diagnostics Market, By End User:

• Hospitals
• Specialty Clinics
• Diagnostics Centre

• Chlamydia Infection Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE